Full-Time
Senior System Test and Validation Engineer
Waters Corporation
10,001+ employees
Analytical instruments, software, and services provider
No salary listed
New Castle, DE, USA
In Person
 QA & Testing (2) |
|---|
| , |
- Five or more years of experience in system testing, validation, or quality engineering for complex products
- Hands-on experience with Linux-based systems, embedded platforms, or Internet of Things devices
- Proven ability to validate end-to-end systems spanning hardware and software
- Experience with test automation and scripting, with Python strongly preferred
- Strong troubleshooting and root cause analysis skills across hardware–software boundaries
- Comfort working in a lab environment with physical devices or instruments
- Design and execute system-level test strategies for Linux-based IoT and connected instrument platforms
- Validate end-to-end workflows across device firmware, edge services, backend APIs, and web UI
- Perform functional, integration, regression, performance, and reliability testing
- Test system behavior under real-world conditions (network latency, device failures, power cycling, upgrades, stress scenarios)
- Test instrument bring-up, initialization, calibration, and recovery across firmware updates and fault conditions
- Validate operation under environmental and operational stress (temperature, vibration, long-duration runs)
- Lead and support cross-disciplinary root cause analysis involving software, firmware, electronics, and mechanical subsystems
- Use logs, telemetry, and lab tools (e.g., multimeter, oscilloscope, logic analyzer) to diagnose complex system issues
- Develop and maintain automated tests at the system, API, and web layers (Python preferred)
- Integrate automated tests into CI/CD pipelines to support continuous quality and release readiness
- Collaborate with DevOps and development teams on build verification, deployment validation, and pre‑production testing
- Support manufacturing and service teams by validating system-level test coverage and diagnostics
- Reproduce field and manufacturing issues in lab environments and help drive corrective actions
- Experience testing web applications, APIs, and backend services
- CI/CD pipeline integration (Jenkins, GitHub Actions, GitLab CI, Azure DevOps)
- Docker or containerized deployments
- Exposure to cloud-connected systems (Amazon Web Services, Microsoft Azure, or Google Cloud Platform)
- Performance, reliability, or long-duration system testing
- Observability tools (logs, metrics, traces)
Waters Corporation provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science research, food and beverage, and environmental sectors. Its products include high-performance analytical instruments like the BioAccord System, paired with software and ongoing support to enable precise, reproducible results. The company operates by selling instruments and software and offering maintenance and services to enhance user experience and reliability. Compared to competitors, Waters offers an integrated package of hardware, software, and service across multiple markets, focused on delivering accurate analyses and end-to-end workflow solutions rather than just standalone devices. Its goal is to unlock the potential of science by solving problems that affect human health and well-being.
Company Size
10,001+
Company Stage
IPO
Headquarters
Milford, Connecticut
Founded
1958
Simplify's Take
What believers are saying
- Q1 2026 organic growth 11% constant currency; raised full-year guidance to 6.5-8%.
- Acquired BD Biosciences unit exceeded revenue by $40M; targeting $55M cost synergies.
- China pharmaceutical revenue grew 50%+ targeting biotech CDMOs and emerging domestic companies.
What critics are saying
- Competitors release comparable MALS and blood culture systems within 12-18 months, eroding differentiation.
- $3.5B debt at 4.3-5.2% creates refinancing cliff 2027-2036 if growth slows.
- BD acquisition integration risks $55M synergy target; supply chain fragmentation could halve realized savings.
What makes Waters Corporation unique
- BD BACTEC FXI detects bloodstream infections 3 hours faster with automated blood volume measurement.
- omniDAWN MALS enables 4x faster large molecule analysis with 10x molar mass improvement.
- ARES-G3 Rheometer reduces testing times 80% while capturing 25,000 data points per second.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Waters Corporation who can refer or advise you
Benefits
Hybrid Work Options
Company News
Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering Photometer, the first extended-range MALS detector designed for ultra high performance liquid chromatography workflows. The device features 18 detection angles and delivers chromatographic run times up to four times faster than conventional methods. The photometer extends UPLC-compatible sizing tenfold, from approximately 50 to 500 nanometres in radius, enabling characterisation of complex molecules including protein aggregates, viral vectors and lipid nanoparticles. It achieves a 10-fold improvement in absolute molar mass measurements whilst reducing sample consumption by 30–50% and solvent use by roughly 40%. The device integrates with Waters UPLC systems and is powered by ASTRA software, supporting analysis across drug discovery, development and quality control. The omniDAWN photometer will be available globally in summer 2026.
Waters Corporation has received FDA clearance for the Onclarity HPV Self-Collection Kit and approval for the BD Onclarity HPV Assay with extended genotyping for at-home use. The kit enables cervical cancer screening from home, addressing barriers that prevent many individuals from routine testing. Approximately 60% of cervical cancer cases occur in unscreened or under-screened individuals. The BD Onclarity HPV Assay is the only FDA-approved test identifying six individual HPV genotypes and three pooled groups, making it the most comprehensive screening tool available in the US. The kit will be available by prescription in coming months and is covered by private insurance, Medicaid and Medicare. Waters is establishing partnerships for broader nationwide access, with patients able to collect samples at home and mail them to laboratories for processing.
Paul Hastings advised underwriters including Barclays Capital, Citigroup Global Markets and J.P. Morgan Securities in a $3.5 billion senior notes offering by Augusta SpinCo Corporation, a Waters Corporation subsidiary. The SEC-registered offering comprises five tranches of senior notes maturing between 2027 and 2036, with interest rates ranging from 4.321% to 5.245%. The notes are guaranteed by Waters and certain subsidiaries. Partner Jeff Ramsay led the Paul Hastings team, which included partners Morgan Bale, Ismael Duran and Daniel Nicholas, along with several associates.
Waters Corporation (WAT), a leading scientific instruments manufacturer, is underperforming the Dow Jones Industrial Average significantly. The stock trades 28.8% below its 52-week high of $414.15 and has declined 22.3% year-to-date, compared to the Dow's 3.8% decline. The Milford, Massachusetts-based company, with a market cap of $28.9 billion, specialises in analytical technologies including liquid chromatography and mass spectrometry for pharmaceutical, life sciences and industrial applications. Despite reporting solid fourth-quarter results with revenue of $932 million, up 7% year-over-year, and adjusted earnings per share rising 10% to $4.53, investor sentiment has soured. Cautious first-quarter guidance and concerns over its acquisition of Becton Dickinson's biosciences unit, which is underperforming expectations, have weighed on the stock.
Waters Corporation reported Q4 revenues of $932.4 million, down 45.4% year on year, meeting analysts' expectations. The analytical instruments manufacturer delivered mixed results, with next quarter's revenue guidance exceeding expectations but earnings per share guidance falling short. The research tools and consumables sector reported a satisfactory Q4 overall, with the 10 tracked stocks beating revenue consensus estimates by 1.2%. However, share prices have struggled, declining 20.9% on average since latest earnings results. Founded in 1958, Waters develops analytical instruments, software and consumables for liquid chromatography, mass spectrometry and thermal analysis. CEO Udit Batra highlighted the company achieved high single-digit revenue growth and double-digit adjusted EPS growth in 2025, with momentum expected to continue into 2026.